NEUVOGEN, Inc.

📍 San Diego, United States👥 13 employees💰 Last funded Sep 2024

NEUVOGEN is an immunoncology company applying a systems approach to develop therapeutic whole cell cancer vaccines to transform how cancer is treated. Our mission is to serve patients with cancer by developing transformative therapies to meaningfully extend their lives. NEUVOGEN’s vision is to revolutionize cancer treatment by harnessing the full power of a patient’s immune system to eliminate cancer from their body. We have taken a fundamentally different approach to solving cancer. Unlike other early-stage immunoncology companies, we try to solve for multiple issues arising from the complexity of cancer biology. Our approach to solving cancer is based on the concept that in order to fully address the complexity of solid tumor cancer biology, many targets and multiple biologic pathways need to be addressed simultaneously. NEUVOGEN is advancing a broad pipeline of therapeutic whole cell cancer vaccine candidates designed to activate the patient’s immune system to target and eliminate existing tumors and prevent future metastases. Our research programs focus on therapeutic cancer vaccines to treat a wide range of tumor types across numerous solid tumor indications.

Total investors

Early stage

Mid stage

Late stage

—

Founded